Squarepoint Ops LLC Grows Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Squarepoint Ops LLC raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 454.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,575 shares of the company’s stock after acquiring an additional 102,929 shares during the quarter. Squarepoint Ops LLC owned 0.18% of Structure Therapeutics worth $6,740,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in GPCR. Seven Fleet Capital Management LP boosted its stake in shares of Structure Therapeutics by 197.8% in the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock valued at $1,442,000 after purchasing an additional 17,800 shares during the period. Wellington Management Group LLP increased its stake in Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after buying an additional 119,146 shares during the period. Handelsbanken Fonder AB acquired a new position in Structure Therapeutics in the 2nd quarter worth $1,041,000. Avidity Partners Management LP purchased a new position in Structure Therapeutics in the 1st quarter valued at about $1,446,000. Finally, Bank of America Corp DE boosted its position in Structure Therapeutics by 617.0% in the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock valued at $10,948,000 after buying an additional 195,454 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $39.55 on Friday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -39.55 and a beta of -1.45. Structure Therapeutics Inc. Sponsored ADR has a one year low of $20.04 and a one year high of $94.90. The stock has a 50-day simple moving average of $49.92 and a 200 day simple moving average of $48.64.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GPCR. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.